Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
It will be the first time ER-100 technology they claim can reverse aging in cells has been tested on a human.
Opening excerpt (first ~120 words) tap to expand
Isabella WardScienceJun 9, 2026 9:23 AMLongevity Startup Doses First Human in Bid to Reverse Age-Related Sight LossThe FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a variety of age-related disease.Photo-Illustration: WIRED Staff; Getty ImagesCommentLoaderSave StorySave this storyCommentLoaderSave StorySave this storyA longevity startup has dosed its first patient with a drug to reverse age-related sight loss.Life Biosciences is testing its ER-100 drug, which the company claims has restored vision in monkeys, for safety and side effects in a study of around 18 adults over the next year.It will be targeting patients with glaucoma and NAION, two conditions that cause damage to…
Excerpt limited to ~120 words for fair-use compliance. The full article is at WIRED.
Discussion
0 commentsMore from WIRED
%252031.jpg&w=800)
